CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for ProKidney Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

ProKidney Corp
2000 Frontis Plaza Blvd., Suite 250
Phone: (336) 999-7028p:336 999-7028 WINSTON-SALEM, NC  27103  United States Ticker: PROKPROK
This company was Merged or Acquired on 7/12/2022.
This is a Subsidiary, click here for the Parent Company
Business Summary
Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202512/31/2024YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
6770 Blank checks
8071 Medical laboratories

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board PabloLegorreta 61
Chief Executive Officer, Director BruceCulleton 57 11/15/2023 11/15/2023
Chief Financial Officer JamesCoulston 49 1/1/2022 1/1/2022
6 additional Officers and Directors records available in full report.

Business Names
Business Name
DNAC
PROK
ProKidney Acquisition Company II, LLC
ProKidney Acquisition Company, LLC
ProKidney Corp. GP Limited
ProKidney LP

General Information
Number of Employees: 204 (As of 12/31/2024)
Outstanding Shares: 294,282,461 (As of 8/12/2025)
Shareholders: 44
Stock Exchange: NASD
Federal Tax Id: 981586514
Fax Number: (302) 636-5454


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, October 31, 2025